Literature DB >> 9010997

Advances in the development and evaluation of bovine herpesvirus 1 vaccines.

J T van Oirschot1, M J Kaashoek, F A Rijsewijk.   

Abstract

This review deals with conventional and modern bovine herpesvirus 1 (BHV1) vaccines. Conventional vaccines are widely used to prevent clinical signs of infectious bovine rhinotracheitis. The use of conventional vaccines, however, does not appear to have resulted in reduction of the prevalence of infection. Novel BHV1 marker vaccines comprise either mutants with a deletion in one of the non-essential genes, or subunit vaccines that contain one or more glycoproteins. These marker vaccines can be used in conjunction with companion diagnostic tests to differentiate between infected and vaccinated cattle. Their efficacy has been evaluated in vaccination-challenge experiments, transmission experiments and in field trials. The results demonstrate that the marker vaccines can contribute to the eventual eradication of BHV1. However, there remains room for improvement of BHV1 marker vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9010997     DOI: 10.1016/s0378-1135(96)01233-3

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  12 in total

Review 1.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

Review 2.  BHV-1: new molecular approaches to control a common and widespread infection.

Authors:  L Turin; S Russo; G Poli
Journal:  Mol Med       Date:  1999-05       Impact factor: 6.354

3.  Expression of the genomic form of the bovine viral diarrhea virus E2 ORF in a bovine herpesvirus-1 vector.

Authors:  Lingshu Wang; J Charles Whitbeck; William C Lawrence; Denys V Volgin; Leonard J Bello
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

4.  A hepadnavirus regulatory element enhances expression of a type 2 bovine viral diarrhea virus E2 protein from a bovine herpesvirus 1 vector.

Authors:  Lingshu Wang; Sreekumar Menon; Steven R Bolin; Leonard J Bello
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Long-term study (2005-2010) on the vaccination with BoHV-1 glycoprotein E-deleted marker vaccine in selected two dairy herds in Turkey.

Authors:  Feray Alkan; S Bilge-Dagalp; Z Karapınar; M O Timurkan; N Coskun; I Burgu
Journal:  Trop Anim Health Prod       Date:  2017-10-25       Impact factor: 1.559

6.  Bovine herpesvirus type 1 (BHV-1) UL49.5 luminal domain residues 30 to 32 are critical for MHC-I down-regulation in virus-infected cells.

Authors:  Huiyong Wei; Ying Wang; Shafiqul I Chowdhury
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

7.  BVDV and BHV-1 infections in dairy herds in northern and northeastern Thailand.

Authors:  J Kampa; K Ståhl; J Moreno-López; A Chanlun; S Aiumlamai; S Alenius
Journal:  Acta Vet Scand       Date:  2004       Impact factor: 1.695

8.  Protection induced by a glycoprotein E-deleted bovine herpesvirus type 1 marker strain used either as an inactivated or live attenuated vaccine in cattle.

Authors:  Sonia Alejandra Romera; Mariana Puntel; Valeria Quattrocchi; Paula Del Médico Zajac; Patricia Zamorano; Javier Blanco Viera; Consuelo Carrillo; Shafiqul Chowdhury; Manuel V Borca; Ana M Sadir
Journal:  BMC Vet Res       Date:  2014-01-08       Impact factor: 2.741

9.  Effects of 3 Different Commercial Vaccines Formulations against BVDV and BHV-1 on the Inflammatory Response of Holstein Heifers.

Authors:  Camila Costa Baccili; Camila Cecilia Martin; Nathália Decaris; Karina Medici Madureira; Christopher Chase; Viviani Gomes
Journal:  Vet Sci       Date:  2019-08-26

10.  Clinical protection against caprine herpesvirus 1 genital infection by intranasal administration of a live attenuated glycoprotein E negative bovine herpesvirus 1 vaccine.

Authors:  Julien Thiry; Maria Tempesta; Michele Camero; Elvira Tarsitano; Benoît Muylkens; François Meurens; Etienne Thiry; Canio Buonavoglia
Journal:  BMC Vet Res       Date:  2007-12-05       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.